RxDoctor Payments Data

Cicily Stanton, MD

Family Medicine · Tampa, FLNPI 1952833113

Payments from drug & device makers

$4,935in general payments, 2019–2025

Across 269 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$586
  • Lilly USA, LLC$574
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$469
  • AbbVie$440
  • Pfizer$319
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,923100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,935 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$129,485
Medicare patients
269
Services billed
2,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$35,840
EliquisApixaban19$27,344
FarxigaDapagliflozin Propanediol11$19,272
Breo ElliptaFluticasone/Vilanterol13$5,291
Rosuvastatin Calcium134$1,995
Valsartan96$1,937
SynthroidLevothyroxine Sodium18$1,239
Atorvastatin Calcium173$1,217
Amlodipine Besylate178$927
Olmesartan Medoxomil41$865
Levothyroxine Sodium88$816
Metoprolol Succinate43$713
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide20$691
Lisinopril87$659
Fluticasone Propionate29$643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,370$35,84026 claims
PfizerEliquis$319$27,34419 claims
AstraZenecaFarxiga$586$19,27211 claims
GSKBreo Ellipta$135$5,29113 claims
AbbVieSynthroid$440$1,23918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →